

# Idiopathic Thrombocytopenic Purpura - Pipeline Review, H2 2020

<https://marketpublishers.com/r/I53480713C93EN.html>

Date: August 2020

Pages: 180

Price: US\$ 2,000.00 (Single User License)

ID: I53480713C93EN

## Abstracts

Idiopathic Thrombocytopenic Purpura - Pipeline Review, H2 2020

### Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Thrombocytopenic Purpura - Pipeline Review, H2 2020, provides an overview of the Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline landscape.

Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from nose and superficial bleeding into skin that appears as a rash of pinpoint sized reddish purple spots, usually on lower legs.

### Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Thrombocytopenic Purpura - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline guide

also reviews of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 9, 11, 10, 1 and 4 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Hematological Disorders).

The pipeline guide reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Idiopathic

Thrombocytopenic Purpura (Hematological Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Idiopathic Thrombocytopenic Purpura (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders)

## **Reasons to Buy**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Hematological Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -

Therapeutics Development

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -

Therapeutics Assessment

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -

Companies Involved in Therapeutics Development

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Drug

Profiles

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant

Projects

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -

Discontinued Products

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product

Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Products under Development by Companies, H2 2020 (Contd..2), H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by 3SBio Inc, H2 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Amgen Inc, H2 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Argenx SE, H2 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H2 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H2 2020 (Contd..1), H2 2020

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

### COMPANIES MENTIONED

3SBio Inc  
Amgen Inc  
Argenx SE  
Beijing Tide Pharmaceutical Co Ltd  
Biotest AG  
BioXpress Therapeutics SA  
Chengdu Rongsheng Pharmaceutical Co Ltd  
Clover Biopharmaceuticals  
CSL Ltd  
Enzene Biosciences Ltd  
GC Pharma  
Genosco Inc  
Genzyme Corp  
HanAll Biopharma Co Ltd  
Hutchison MediPharma Ltd  
Iltoo Pharma  
Jiangsu Hengrui Medicine Co Ltd  
Kezar Life Sciences Inc  
KM Biologics Co Ltd  
Momenta Pharmaceuticals Inc  
Novartis AG

Pfizer Inc  
Pharmagenesis Inc  
Pharmapraxis  
Principia Biopharma Inc  
Protalex Inc  
Qilu Pharmaceutical Co Ltd  
Rigel Pharmaceuticals Inc  
Shandong Quangang Pharmaceutical Co Ltd  
Sichuan Kelun Pharmaceutical Co Ltd  
Taiho Pharmaceutical Co Ltd  
Takeda Pharmaceutical Co Ltd  
UCB SA



## I would like to order

Product name: Idiopathic Thrombocytopenic Purpura - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/I53480713C93EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I53480713C93EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970